Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis

Neurology

Volumn 49, Issue 2, 1997, Pages 378-385

  Weinshenker, B G ^a   Wingerchuk, D M ^a   Liu, Q ^b,c   Bissonet, A S ^a   Schaid, D J ^a   Sommer, S S ^b,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DNA FINGERPRINTING; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0030766640     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.378     Document Type: Article

References (44)

1. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146.
2. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114: 1045-1056.
3. Runmarker B, Martinsson T, Wahlstrom J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994;241:385-390.
4. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;i:1313-1315.
5. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 1994;54:1-17.
6. Oksenberg JR, Begovich AB, Erlich HA, Steinman L. Genetic factors in multiple sclerosis. JAMA 1993;270:2362-2369.
7. Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. A comparison of sporadic and familial multiple sclerosis. Neurology 1990;40:1354-1358.
8. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of Interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
9. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
10. Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 1993;87: 281-285.
11. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992;3:523-531.
12. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol 1992;49:265-270.
13. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
14. Roth MP, Nagueira L, Coppin H, et al. Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol 1994;57:93-99.
15. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990;40:780-786.
16. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L. Impairment, disability and handicap in multiple sclerosis: a population based study in Olmsted County, Minnesota. Neurology 1994;44:28-33.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18. Gustafson S, Proper JA, Bowie EJW, Sommer SS. Parameters affecting the yield of DNA from human blood. Anal Biochem 1987;165:294-299.
19. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: structure homology and chromosome localization. Nucleic Acids Res 1985;13:6361-6373.
20. Liu Q, Feng J, Sommer SS. Bidirectional dideoxy fingerprinting (Bi-ddF): a rapid method for quantitative detection of mutations in genomic regions of 300-600 bp. Hum Mol Genet 1996;5:107-114.
21. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995; 13:179-200.
22. Garchon HJ. Non-MHC-linked genes in autoimmune diseases. Curr Opin Immunol 1993;5:894-899.
23. Shultz LD. Immunological mutants of the mouse. Am J Anat 1991;191:303-311.
24. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-806.
25. Olerup O, Hillert J, Fredrikson S, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 1989;86:7113-7117.
26. Weinshenker BG, Santrach P, Schaid D, Rodriguez M. Association between class II major histocompatibility complex polymorphisms and the course of multiple sclerosis [abstract]. Neurology 1995;45(suppl 4):384A.
27. Runmarker B, Martinsson T, Wahlstrom J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994;241:385-390.
28. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346.
29. Lavi E, Suzumura A, Murasko DM, et al. Tumor necrosis factor induces the expression of MHC class I antigens on mouse astrocytes. J Neuroimmunol 1988;18:245-253.
30. Benveniste EN, Sparacio SM, Bethea JR. Tumor necrosis factor enhances interferon-gamma mediated class II antigen expression on astrocytes. J Neuroimmunol 1989;25:209-219.
31. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-1725.
32. Zipp F, Weber F, Huber S, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor-necrosis factor α by HLA-DR2+ T-cells. Ann Neurol 1995;38: 723-730.
33. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the humantumor necrosis factor α promoter region is strongly associated with HLA-A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
34. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995;42:501-504.
35. Brinkman BM, Kaijzel EL, Huizinga TW, Giphart MJ, Breedveld FC, Venveij CL. Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFα) gene. Hum Genet 1995;96:493.
36. McGuire W, Hill AVS, Allsop CEM, Greenwood BM, Kwiatkowski D. Variation in the TNFα promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-511.
37. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor a promoter base on transcriptional activation. Proc Natl Acad Sci USA 1997; 94:3195-3199.
38. Schaid DJ, Sommer SS. Genotype relative risks: methods for design and analysis of candidate-gene association studies. Am J Hum Genet 1993;53:1114-1126.
39. Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. A population-based case-control study of the tumor necrosis factor alpha -308 polymorphism in multiple sclerosis. Neurology 1997;49:626-628.
40. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha -308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995;63:143-147.
41. Sobell JL, Heston LL, Sommer SS. Delineation of genetic predisposition to multifactorial disease: a general approach on the threshold of feasibility. Genomics 1992;12:1-6.
42. Sawcer S, Jones H, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-468.
43. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet 1996;13: 469-471.
44. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-476.